ArticleFrontiers in cardiovascular medicine2026
Association of plasma homocysteine with the atherogenic index of plasma and modification by body mass index: a cross-sectional study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Hyperhomocysteinemia is generally considered an independent risk factor for cardiovascular disease; nevertheless, the independent connection between plasma homocysteine (HCY) and the atherogenic index of plasma (AIP), which integrates the risk of atherogenic lipids, has not been completely elucidated. The potential biological mechanisms relating HCY to AIP also need to be clarified further. This investigation investigates the relation between plasma HCY and AIP in a general adult group, examines whether inflammation and liver function statistically influence this relation, and evaluates the effect of body mass index (BMI) on the relationship. In this cross-sectional study, 887 adults were analyzed in the final stage. Outliers were excluded based on a lenient threefold interquartile range criterion to maintain biologically reasonable variations. The relationship between HCY and continuous AIP was analyzed by multiple linear regression, while the relation with high AIP risk was studied by logistic regression. Mediation analysis was performed using the bootstrap method, with white blood cell count (WBC) and alanine aminotransferase (ALT) as putative mediators. Subgroup analysis and formal interaction tests were conducted to investigate if the association between HCY and AIP varied among different clinical groups. Results: Plasma HCY was positively correlated with AIP ( Conclusion: Plasma HCY was independently and positively associated with AIP, and this relationship was more pronounced among overweight or obese participants. The association appeared to be driven mainly by a direct pathway, with no statistically significant mediation through the selected markers of inflammation or liver function. These findings suggest that BMI should be considered when evaluating the lipid-related atherogenic risk associated with elevated HCY.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.